| Ident. | Authors (with country if any) | Title |
|---|
| 000064 |
Ana Budimir [Croatie] | Metal ions, Alzheimer's disease and chelation therapy |
| 000147 |
Michael S. Remple [États-Unis] ; Courtney H. Bradenham [États-Unis] ; C. Chris Kao [États-Unis] ; P. David Charles [États-Unis] ; Joseph S. Neimat [États-Unis] ; Peter E. Konrad [États-Unis] | Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression |
| 000265 |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
| 000268 |
Elisa Garbayo [Espagne] ; Eduardo Ansorena [Espagne] ; Jose Luis Lanciego [Espagne] ; María Jose Blanco-Prieto [Espagne] ; María S. Aymerich [Espagne] | Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease |
| 000329 |
S. Wailke [Allemagne] ; J. Herzog [Allemagne] ; K. Witt [Allemagne] ; G. Deuschl [Allemagne] ; J. Volkmann [Allemagne] | Effect of controlled‐release levodopa on the microstructure of sleep in Parkinson’s disease |
| 000347 |
S. Iraola-Guzmán [Espagne] ; X. Estivill [Espagne] ; R. Rabionet [Espagne] | DNA methylation in neurodegenerative disorders: a missing link between genome and environment? |
| 000385 |
Raymond T. Bartus [États-Unis] ; Christopher D. Herzog [États-Unis] ; Yaping Chu [États-Unis] ; Alistair Wilson [États-Unis] ; Lamar Brown [États-Unis] ; Joao Siffert [États-Unis] ; Eugene M. Johnson Jr. [États-Unis] ; C. Warren Olanow [États-Unis] ; Elliott J. Mufson [États-Unis] ; Jeffrey H. Kordower [États-Unis] | Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains |
| 000505 |
Hugo Vicente Miranda [Portugal] ; Tiago Fleming Outeiro [Portugal] | The sour side of neurodegenerative disorders: the effects of protein glycation |
| 000523 |
William Dauer [États-Unis] ; Cherry Cheng-Ying Ho [États-Unis] | The biology and pathology of the familial Parkinson's disease protein LRRK2 |
| 000576 |
Anna Martínez [Espagne] ; Manuel Portero-Otin [Espagne] ; Reinald Pamplona [Espagne] ; Isidre Ferrer [Espagne] | Protein Targets of Oxidative Damage in Human Neurodegenerative Diseases with Abnormal Protein Aggregates |
| 000648 |
Jean-Marc Taymans [États-Unis, Belgique] ; Mark R. Cookson [États-Unis] | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau |
| 000801 |
Lena F. Burbulla [Allemagne] ; Guido Krebiehl [Allemagne] ; Rejko Krüger [Allemagne] | Balance is the challenge – The impact of mitochondrial dynamics in Parkinson’s disease |
| 000954 |
David Weise [Allemagne] ; Reinhard Lorenz [Allemagne] ; Mira Schliesser [Allemagne] ; Andreas Schirbel [Allemagne] ; Karlheinz Reiners [Allemagne] ; Joseph Classen [Allemagne] | Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease |
| 000A49 |
Payal N. Gandhi [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease |
| 000B15 |
Nadja Van Camp [Belgique, France] ; Ines Blockx [Belgique] ; Marleen Verhoye [Belgique] ; Cindy Casteels [Belgique] ; Frea Coun [Belgique] ; Alexander Leemans [Royaume-Uni, Pays-Bas] ; Jan Sijbers [Belgique] ; Veerle Baekelandt [Belgique] ; Koen Van Laere [Belgique] ; Annemie Van Der Linden [Belgique] | Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract |
| 000B66 |
Koen Bossers [Pays-Bas] ; Gideon Meerhoff ; Rawien Balesar [Pays-Bas] ; Jeroen W. Van Dongen [Pays-Bas] ; Chris G. Kruse [Pays-Bas] ; Dick F. Swaab [Pays-Bas] ; Joost Verhaagen | Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death |
| 000C54 |
Payal N. Gandhi [États-Unis] ; Xinglong Wang [États-Unis] ; Xiongwei Zhu [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules |
| 000C78 |
Carola Schiesling ; Nicole Kieper ; Kay Seidel [Allemagne] ; Rejko Krüger | Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease |
| 000C94 |
Eleonora Bazzini [Italie] ; Alberta Samuele [Italie] ; Marcella Granelli [Italie] ; Giovanna Levandis [Italie] ; Marie-Therese Armentero [Italie] ; Giuseppe Nappi [Italie] ; Fabio Blandini [Italie] | Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine |
| 000E30 |
Darcy Litteljohn [Canada] ; Emily N. Mangano [Canada] ; Shawn Hayley [Canada] | Cyclooxygenase‐2 deficiency modifies the neurochemical effects, motor impairment and co‐morbid anxiety provoked by paraquat administration in mice |
| 000F30 |
E-K Tan [Singapour] | The role of common genetic risk variants in Parkinson disease |
| 000F72 |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
| 000F92 |
Eng-King Tan [Singapour] ; Lisa M. Skipper [États-Unis] | Pathogenic mutations in Parkinson disease |
| 001000 |
P. T. T. Ly [Canada] ; S. Singh [Canada] ; C. A. Shaw [Canada] | Novel environmental toxins: Steryl glycosides as a potential etiological factor for age‐related neurodegenerative diseases |
| 001238 |
D. Gosal [Irlande (pays)] ; O. A. Ross [États-Unis] ; M. Toft [États-Unis, Norvège] | Parkinson's disease: the genetics of a heterogeneous disorder |
| 001305 |
S. G. Mueller [États-Unis] ; N. Schuff [États-Unis] ; M. W. Weiner [États-Unis] | Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS |
| 001357 |
B. Feldman [Israël] ; J. Chapman [Israël] ; A. D. Korczyn [Israël] | Apolipoprotein ɛ4 advances appearance of psychosis in patients with Parkinson's disease |
| 001512 |
K. Michno [Canada] ; D. Van De Hoef [Canada] ; H. Wu ; Gl Boulianne [Canada] | Demented flies? using Drosophila to model human neurodegenerative diseases |
| 001549 |
P. M. Carvey [États-Unis] ; C. H. Zhao [États-Unis] ; B. Hendey [États-Unis] ; H. Lum [États-Unis] ; J. Trachtenberg [États-Unis] ; B. S. Desai [États-Unis] ; J. Snyder [États-Unis] ; Y. G. Zhu [États-Unis] ; Z. D. Ling [États-Unis] | 6‐Hydroxydopamine‐induced alterations in blood–brain barrier permeability |
| 001657 |
Ulrike Sommer [Allemagne] ; Thomas Hummel [Allemagne] ; Katja Cormann [Allemagne] ; Antje Mueller [Allemagne] ; Johannes Frasnelli [Allemagne] ; Joachim Kropp [Allemagne] ; Heinz Reichmann [Allemagne] | Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT |
| 001726 |
Peter Teismann [États-Unis] ; Kim Tieu [États-Unis] ; Oren Cohen [États-Unis] ; Dong-Kug Choi [États-Unis] ; Du Chu Wu [États-Unis] ; Daniel Marks [États-Unis] ; Miquel Vila [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Serge Przedborski [États-Unis] | Pathogenic role of glial cells in Parkinson's disease |
| 001734 |
Christopher Hawkes [Royaume-Uni] | Olfaction in neurodegenerative disorder |
| 001921 |
Andrew West [États-Unis] ; Magali Periquet [France] ; Sarah Lincoln [États-Unis] ; Christoph B. Lücking [France, Allemagne] ; David Nicholl [Royaume-Uni] ; Vincenzo Bonifati ; Nina Rawal [France] ; Thomas Gasser [Allemagne] ; Ebba Lohmann [France] ; Jean-François Deleuze [France] ; Demetrius Maraganore [États-Unis] ; Allan Levey [Géorgie (pays)] ; Nick Wood [Royaume-Uni] ; Alexandra Dürr [France] ; John Hardy [États-Unis] ; Alexis Brice [France] ; Matt Farrer [États-Unis] | Complex relationship between Parkin mutations and Parkinson disease |
| 001A01 |
Robert Layfield ; Andrew Alban ; R. John Mayer ; James Lowe [Royaume-Uni] | The ubiquitin protein catabolic disorders |
| 001A17 |
Diana Frechilla [Espagne] ; Almudena Cobreros [Espagne] ; Laura Saldise [Espagne] ; Rosario Moratalla [Espagne] ; Ricardo Insausti [Espagne] ; M-Rosario Luquin [Espagne] ; Joaquín Del Río [Espagne] | Serotonin 5‐HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys |
| 001A91 |
Alexandra Roedter [Allemagne] ; Christian Winkler [Allemagne] ; Madjid Samii [Allemagne] ; Gerhard F. Walter [Allemagne] ; Almuth Brandis [Allemagne] ; Guido Nikkhah [Allemagne] | Comparison of unilateral and bilateral intrastriatal 6‐hydroxydopamine‐induced axon terminal lesions: Evidence for interhemispheric functional coupling of the two nigrostriatal pathways |
| 002155 |
S. Hunot [France] ; F. Boissière [France] ; B. Faucheux [France] ; B. Brugg [France] ; A. Mouatt-Prigent [France] ; Yves Agid [France] ; E. C. Hirsch [France] | Nitric oxide synthase and neuronal vulnerability in parkinson's disease |
| 002160 |
S. Kösel [Allemagne] ; C. B. Lücking [Allemagne] ; R. Egensperger [Allemagne] ; P. Mehraein [Allemagne] ; M. B. Graeber [Allemagne] | Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy‐body Parkinsonism |
